<DOC>
	<DOCNO>NCT00802243</DOCNO>
	<brief_summary>Bullous pemphigoid ( BP ) common blister auto-immune disease skin incidence estimate 400 new case per year . Topical corticosteroid therapy consider standard treatment bullous pemphigoïd 2002 . Topical corticosteroid require initial large hospitalization acute phase rehospitalization relapse . The usefulness immunosuppressive drug suggest uncontrolled study . In way , leflunomide could alternative therapy , reduce relapse and/or resistance risk . This study could prove efficacity leflunomide , associate short time topical corticosteroid .</brief_summary>
	<brief_title>Leflunomide Associated With Topical Corticosteroids Bullous Pemphigoid</brief_title>
	<detailed_description>Pre-inclusion stage : Case history , clinical examination , laboratory study , inclusion criterion check . Inclusion stage : Inclusion exclusion criterion check , clinical examination , disease follow-up , write inform consent . Ambulatory hospitalisation , laboratory study . Treatment follow-up patient . Clobetasol propionate cream application leflunomide introduction . After inclusion , treatment begin 40 g topical corticosteroid per day 20 mg leflunomide per day . Topical corticosteroid progressively decrease 5 month stop . Follow-up : monthly one year department dermatology , university hospital ( clinical examination , laboratory study ) .</detailed_description>
	<mesh_term>Pemphigoid , Bullous</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>Adult ≥ 65 year old Bullous pemphigoid : Newly diagnose bullous pemphigoid : No treatment topical corticosteroid therapy le one month BP diagnose : Resistance BP treatment recurrence 6 month least diagnosis Follow monthly one year accept Written Inform Consent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Bullous pemphigoid</keyword>
	<keyword>leflunomide</keyword>
	<keyword>corticosteroid treatment reduction</keyword>
	<keyword>Patients screen : physician different department hospital , liberal dermatologist general practicioners .</keyword>
	<keyword>Phase I : Patients refer investigator Dupuytren Hospital Dermatology Department .</keyword>
	<keyword>Phase II : Patients refer investigator Purpan ( Toulouse ) , Haut Leveque ( Pessac ) Dupuytren ( Limoges ) Hospitals .</keyword>
</DOC>